At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Cenicriviroc 150 mgdrug
Likely dose
Cenicriviroc 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
In Brief
A Phase 2 clinical trial evaluating Cenicriviroc 150 mg for Primary Sclerosing Cholangitis. Completed, enrolled 24 participants across 9 sites in 2 countries.
Detailed Summary
This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sclerosing Cholangitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionAug 2017
TodayJul 2026
First PostedJan 12, 2016
Enrollment StartMar 14, 2016
Primary CompletionAug 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.5 years ago
Interventions
Cenicriviroc 150 mgdrug
One tablet of CVC 150 mg once daily taken with food in the morning.